FDA Alignment to Advance ProstACT Global Phase 3 Trial

RegulatorypositiveTLX591-TxPositive

AI Analysis

Summary

Telix Pharmaceuticals announced successful FDA Type B meeting alignment to advance its ProstACT Global Phase 3 trial of TLX591-Tx, a lutetium-177 therapeutic for metastatic castration resistant prostate cancer, with positive review of Part 1 safety/dosimetry data and Part 2 protocol design.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Successful Type B meeting with FDA to review Part 1 safety and dosimetry data and Part 2 protocol design of ProstACT Global Phase 3 trial

Importance:7/10

Sentiment:

0.75

FDAregulatory alignmentPhase 3oncologyprostate cancerType B meeting

Related Companies

$TLX

Read the original article

Published by GlobeNewswire Clinical Studies on July 2, 2026 1:31 AM

Read Original